04:33 PM EDT, 03/25/2024 (MT Newswires) -- Amneal Pharmaceuticals ( AMRX ) said Monday it has received approval from the US Food and Drug Administration for the abbreviated new drug application for ciprofloxacin and dexamethasone otic suspension.

The product is indicated for the treatment of ear infections in pediatric, adult and elderly patients, the drugmaker said.

Shares of the company rose 2% in after-hours activity.

Price: 6.03, Change: +0.12, Percent Change: +2.03